Latest developments and emerging treatment options in the management of stomach cancer

References

• KamangarFDoresGMAndersonWFPatterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the worldJ Clin Oncol200624142137215016682732
   PubMed Web of Science ®Google Scholar
• RoderDMThe epidemiology of gastric cancerGastric Cancer20025Suppl 151112772880
   PubMedGoogle Scholar
• AdachiYKitanoSSugimachiKSurgery for gastric cancer: 10-year experience worldwideGastric Cancer20014416617411846059
   PubMedGoogle Scholar
• CraanenMEDekkerWBlokPFerwerdaJTytgatGNTime trends in gastric carcinoma: changing patterns of type and locationAm J Gastroenterol19928755725791306644
   PubMed Web of Science ®Google Scholar
• CunninghamDAllumWHStenningSPPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551112016822992
   PubMed Web of Science ®Google Scholar
• YchouMBoigeVPignonJPPerioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: a FNCLCC and FFCD multicenter phase III trialJ Clin Oncol201129131715172121444866
   PubMed Web of Science ®Google Scholar
• SchuhmacherCGretschelSLordickFNeoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954J Clin Oncol201028355210521821060024
   PubMed Web of Science ®Google Scholar
• NakajimaTKinoshitaTNashimotoARandomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancerBr J Surg200794121468147617948223
   PubMed Web of Science ®Google Scholar
• SakuramotoSSasakoMYamaguchiTAdjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidineN Engl J Med2007357181810182017978289
   PubMed Web of Science ®Google Scholar
• PaolettiXObaKBurzykowskiTBenefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysisJAMA2010303171729173720442389
   PubMed Web of Science ®Google Scholar
• MacdonaldJSSmalleySRBenedettiJChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med20013451072573011547741
   PubMed Web of Science ®Google Scholar
• ChauINormanARCunninghamDWatersJSOatesJRossPJMultivariate prognostic factor analysis in locally advanced and meta-static esophago-gastric cancer – pooled analysis from three multicenter, randomized, controlled trials using individual patient dataJ Clin Oncol200422122395240315197201
   PubMed Web of Science ®Google Scholar
• PyrhonenSKuitunenTNyandotoPKouriMRandomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBr J Cancer19957135875917533517
   PubMed Web of Science ®Google Scholar
• GlimeliusBEkstromKHoffmanKRandomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnn Oncol1997821631689093725
   PubMed Web of Science ®Google Scholar
• MuradAMSantiagoFFPetroianuARochaPRRodriguesMARauschMModified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer1993721 37418508427
   PubMed Web of Science ®Google Scholar
• WagnerADGrotheWHaertingJKleberGGrotheyAFleigWEChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol20062418 2903290916782930
   PubMed Web of Science ®Google Scholar
• VanhoeferURougierPWilkeHFinal results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative GroupJ Clin Oncol200018142648265710894863
   PubMed Web of Science ®Google Scholar
• WatersJSNormanACunninghamDLong-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trialBr J Cancer1999801–226927210390007
   PubMed Web of Science ®Google Scholar
• RothADFazioNStuppRDocetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer ResearchJ Clin Oncol200725223217322317664469
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol20062431 4991499717075117
   PubMed Web of Science ®Google Scholar
• AjaniJAMoiseyenkoVMTjulandinSClinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study GroupJ Clin Oncol200725223205320917664467
   PubMed Web of Science ®Google Scholar
• OvermanMJKazmiSMJhambJWeekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancerCancer201011661446145320108336
   PubMed Web of Science ®Google Scholar
• TebbuttNCCumminsMMSourjinaTRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialBr J Cancer2010102347548120068567
   PubMed Web of Science ®Google Scholar
• LiCPChenJSChenLTA phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancerBr J Cancer201010391343134820924378
   PubMed Web of Science ®Google Scholar
• De GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol200018162938294710944126
   PubMed Web of Science ®Google Scholar
• GuimbaudRBORebischungCPlanned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancersJ Clin Oncol20092715S4533
   Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• MalikIBernalPByrdJA phase I study of docetaxel, oxaliplatin, and capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junctionCancer Invest201028883383820839949
   PubMed Web of Science ®Google Scholar
• AndersenMSchonnemannKRYilmazMJensenHAVestermarkLWPfeifferPPhase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancerActa Oncol20104981246125220429725
   PubMed Web of Science ®Google Scholar
• DankMZaluskiJBaroneCRandomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junctionAnn Oncol20081981450145718558665
   PubMed Web of Science ®Google Scholar
• GuimbaudRBouchéORebischungCPlanned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancersJ Clin Oncol.20092715 Suppl Abstract 4533.
   Web of Science ®Google Scholar
• BokuNYamamotoSShiraoKRandomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)J Clin Oncol20072518S96517350945
   PubMed Web of Science ®Google Scholar
• CassidyJSaltzLTwelvesCEfficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patientsAnn Oncol2011 [Epub ahead of print].
   Google Scholar
• KangYKKangWKShinDBCapecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trialAnn Oncol200920466667319153121
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• AjaniJARodriguezWBodokyGMulticenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trialJ Clin Oncol20102891547155320159816
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• KangYOhtsuAVan CutsemEAVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)J Clin Oncol.20102818S Abstr 4007.
   Google Scholar
• El-RayesBFZalupskiMBekai-SaabTA phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancersAnn Oncol201021101999200420332133
   PubMed Web of Science ®Google Scholar
• SunWPowellMO’DwyerPJCatalanoPAnsariRHBensonAB3rdPhase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol201028182947295120458043
   PubMed Web of Science ®Google Scholar
• BramhallSRHallisseyMTWhitingJMarimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trialBr J Cancer200286121864187012085177
   PubMed Web of Science ®Google Scholar
• UedaSHironakaSBokuNFukutomiAYoshinoTOnozawaYCombination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancerGastric Cancer20069320320716952039
   PubMedGoogle Scholar
• KunisakiCImadaTYamadaRPhase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinomaAnticancer Res20052542973297716080554
   PubMed Web of Science ®Google Scholar
• GiulianiFMolicaSMaielloEIrinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. 2106)Am J Clin Oncol200528658158516317268
   PubMed Web of Science ®Google Scholar
• KoderaYItoSMochizukiYA phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)Anticancer Res2007274C 2667267117695430
   PubMed Web of Science ®Google Scholar
• ParkSHKimYSHongJMitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II studyAnticancer Drugs200819330330718510177
   PubMed Web of Science ®Google Scholar
• RosatiGBilanciaDGermanoDReduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II studyAnn Oncol.200718Suppl 6vi128vi13217591806
   PubMed Web of Science ®Google Scholar
• SchoennemannKRBjerregaardJKHansenTPBiweekly cetuximab and irinotecan as second-line therapy in patients with gastroesophageal cancer previously treated with platinumGastric Cancer2011 [Epub ahead of print].
   Google Scholar
• BangYJKangYKKangWKPhase II study of sunitinib as second-line treatment for advanced gastric cancerInvest New Drugs.2010 [Epub ahead of print].
   Google Scholar
• OttKFinkUBeckerKPrediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trialJ Clin Oncol200321244604461014673049
   PubMed Web of Science ®Google Scholar
• ShimadaHOkazumiSKoyamaMMurakamiKJapanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of (1) F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literatureGastric Cancer2011141132121331531
   PubMed Web of Science ®Google Scholar